New protein kinase inhibitor for metastatic colorectal cancer

摘要

PATIENTS with metastatic colorectal cancer who cannot be treated with current therapies now have the option of treatment with regorafenib. Regorafenib is an inhibitor of multiple protein kinases, including kinases involved in blood vessel formation around tumours, oncogenesis and the tumour microenvironment. It is indicated for patients with metastatic colorectal cancer who have been treated with all available therapies but have gone on to experience disease progression, or for patients who are not candidates for the remaining standard therapies.